Immunohistochemical determination of p53 protein does not predict clinicalresponse in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination

Citation
S. Cascinu et al., Immunohistochemical determination of p53 protein does not predict clinicalresponse in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination, ANN ONCOL, 11(8), 2000, pp. 1053-1056
Citations number
16
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
ANNALS OF ONCOLOGY
ISSN journal
09237534 → ACNP
Volume
11
Issue
8
Year of publication
2000
Pages
1053 - 1056
Database
ISI
SICI code
0923-7534(200008)11:8<1053:IDOPPD>2.0.ZU;2-L
Abstract
Background: We assessed the hypothesis that a compromised p53 function coul d account for the non response of colon cancer patients with low thymidylat e synthase (TS) expression receiving a bolus 5-fluorouracil (5-FU)-leucovor in (LV) combination. Patients and methods: The study population consisted of 41 patients with un resectable metastatic colon cancer, homogeneosuly, treated with bolus 5-FU and LV. Results: Twenty-seven patients (66%) showed high levels of TS expression. T he difference in the proportion of objective responses between patients wit h low (CR + PR: 7 of 14, 50%) and high (CR + PR: 0 of 27) TS levels was sta tistically significant (P = 0.0001, chi-square test). p53 nuclear overexpre ssion was found in 27 of 41 patients (66%). No differences were observed in p53 overexpression in patients with high (66%) or low (66%) TS expression. p53 status was not found to be associated with response even in patients w ith low TS expression. Conclusions: p53 status measured by immunohistochemistry does not seem to b e useful to identify unresponsive patients with low TS expression.